Emerging perioperative therapeutic approaches in muscle invasive bladder cancer
Bladder cancer is a significant healthcare burden with more than 17,000 deaths in the United States in 2018.Patients who are diagnosed with muscle invasive bladder cancer (MIBC) have a high rate of micro-metastatic disease and have a much poorer prognosis compared with patients who have less advanced lesions.Historically, neoadjuvant administration